To the Editor.—
We read with interest the letter from Frattola et al (35:60, 1978) about the mechanisms of action of bromocriptine in Huntington's chorea. According to the authors, bromocriptine should be considered as a partial dopaminergic agonist, with a "biphasic effect" that depends on the dosage.Similar effects have been observed by us after the administration of bromocriptine to 11 patients affected by Huntington's chorea1: involuntary movements showed a good improvement when the daily dosage of bromocriptine was low (< 40 mg/day), whereas a slight worsening was seen after the administration of higher dosages (40 to 60 mg/day). Moreover, CSF HVA levels substantially increased after the low-dosage treatment with bromocriptine, and substantially decreased when a high dosage was used.These data, namely, the increase in CSF HVA levels associated with the clinical improvement of choreic movements, suggest that dopamine-sensitive receptors in the neostriatum are blocked, from a low
Albano C, Cocito L. Huntington's Chorea and Bromocriptine. Arch Neurol. 1979;36(5):322. doi:10.1001/archneur.1979.00500410100024
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: